NetraMark Holdings Inc C.AIAI

Alternate Symbol(s): AINMF

Technology Software - Application

NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.

CSE:AIAI - Post by User

NetraMark Holdings Inc > Conference Call Dec 5 9:00 am ET

<< Previous

Bullboard Posts

Next >>

Comment by windymayor1on Dec 05, 2024 3:27pm

326 Views

Post# 36347863

RE:RE:RE:Conference Call Dec 5 9:00 am ET

I would say yes.
They are pursuing ISTAND.- Innovative Science and Technology Approachs for New Drugs program..
Submitting to FDA in Jan.
Its like the CSA standard for achieving Trial success and would give them regulator validation.
Imagine if every biotech/pharma trial uses AIAi?!
10,000 trials/year x $400k.
Mindboggling potential.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks